Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 52

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Glioblastoma multiforme

Not yet recruiting

Study of autologous mature dendritic cell vaccine plus atezolizumab in patients with recurrent glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Heinrich-Heine-Universitaet Duesseldorf

Central nervous system vasculitis

Not yet recruiting

Rituximab versus azathioprine for remission maintenance in patients with primary angiitis of the central nervous system – randomized controlled trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azathioprine
  • Sponsor:Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Cerebrovascular accident

Not yet recruiting

Rimonabant for Improving Walking Ability in Post‑Stroke Patients in the Chronic Phase

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Dementia Alzheimer's type

Not yet recruiting

A Phase 2 Study of TML-6 in Adults with Early Alzheimer’s Disease to Evaluate Safety, Tolerability, and Efficacy

Investigational
Countries:SwedenSweden
  • Participants:65+ years

Amyotrophic lateral sclerosis

Not yet recruiting

Randomized Placebo‑Controlled Trial of Colchicine to Slow Disease Progression in Adults with Amyotrophic Lateral Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Cerebrovascular accident

Not yet recruiting

Effect of Rimonabant on Functional Recovery in Subacute Stroke Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Neuroblastoma

Not yet recruiting

Feasibility Study of AloCelyvir and Autologous Tumor‑Infiltrating T Lymphocytes in Children and Young Adults with High‑Risk Relapsed/Refractory Neuroblastoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa

Epilepsy

Not yet recruiting

Long‑Term Safety and Tolerability of Probenecid (PTI5803) as Adjunctive Therapy in Patients ≥14 Years with Drug‑Resistant Focal Epilepsy due to Focal Cortical Dysplasia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Sponsor:Panntherapi

Neuromyelitis optica spectrum disorder+1

Not yet recruiting

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Parkinson's disease

Not yet recruiting

Effect of botulinum toxin type A - haemagglutinin complex on refractory upper‑limb resting tremor in Parkinson disease patients (drug‑combination study)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nitrous Oxide
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Spinal muscular atrophy

Not yet recruiting

Study of BIIB115 in patients aged 15‑60 years with spinal muscular atrophy who are treatment‑naïve or previously treated with risdiplam

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Huntington's disease

Not yet recruiting

Phase 2/3 Randomized Study of SKY-0515 for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.